semaglutide api manufacturing China leads in GLP-1 | Gaurav Monga posted on the topic The Wild East of semaglutide

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial

62 , e1700770 (2018)

[16] Stopping semaglutide at 68 weeks leads to significant weight regain

Some researchers add an extra 0.1mL of bacteriostatic water to compensate, accepting a slightly lower concentration (3.23mg/mL instead of 3.33mg/mL) in exchange for recovering nearly all the peptide

2 For non-diabetic patients prescribed liraglutide, we observed an increased likelihood of delayed gastric emptying (139%) and ileus (32%), but no difference in likelihood of gallstones when compared to those on a non-GLP-1 weight loss medication